Production (Stage)
Dianthus Therapeutics, Inc.
DNTH
$18.31
-$0.98-5.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.52M | 6.24M | 5.37M | 4.12M | 3.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.52M | 6.24M | 5.37M | 4.12M | 3.22M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.52M | 6.24M | 5.37M | 4.12M | 3.22M |
| SG&A Expenses | 26.69M | 24.99M | 22.80M | 24.99M | 21.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.72M | 108.10M | 88.27M | 72.88M | 61.56M |
| Operating Income | -117.20M | -101.86M | -82.90M | -68.76M | -58.34M |
| Income Before Tax | -100.73M | -84.97M | -67.09M | -56.68M | -50.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.73 | -84.97 | -67.09 | -56.68 | -50.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.73M | -84.97M | -67.09M | -56.68M | -50.21M |
| EBIT | -117.20M | -101.86M | -82.90M | -68.76M | -58.34M |
| EBITDA | -117.10M | -101.77M | -82.81M | -68.68M | -58.26M |
| EPS Basic | -2.89 | -2.60 | -2.50 | -5.54 | -17.76 |
| Normalized Basic EPS | -1.84 | -1.64 | -1.58 | -3.48 | -11.11 |
| EPS Diluted | -2.89 | -2.60 | -2.50 | -5.54 | -17.76 |
| Normalized Diluted EPS | -1.84 | -1.64 | -1.58 | -3.48 | -11.11 |
| Average Basic Shares Outstanding | 139.29M | 129.16M | 108.95M | 78.62M | 45.27M |
| Average Diluted Shares Outstanding | 139.29M | 129.16M | 108.95M | 78.62M | 45.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |